Suzanne Conzen to Antineoplastic Combined Chemotherapy Protocols
This is a "connection" page, showing publications Suzanne Conzen has written about Antineoplastic Combined Chemotherapy Protocols.
Connection Strength
0.521
-
A randomized phase II trial of nab-paclitaxel with or without mifepristone for advanced triple-negative breast cancer. Breast Cancer Res Treat. 2025 May; 211(1):111-119.
Score: 0.108
-
Investigation of selective glucocorticoid receptor modulation in high-grade serous ovarian cancer PDX models. J Gynecol Oncol. 2025 Jan; 36(1):e4.
Score: 0.103
-
Phase II trial of tamoxifen, etoposide, mitoxantrone, and cisplatin in patients with metastatic breast carcinoma. Cancer. 1996 Nov 01; 78(9):1906-11.
Score: 0.061
-
Glucocorticoid receptor activation inhibits chemotherapy-induced cell death in high-grade serous ovarian carcinoma. Gynecol Oncol. 2015 Sep; 138(3):656-62.
Score: 0.055
-
Gene expression of peripheral blood cells reveals pathways downstream of glucocorticoid receptor antagonism and nab-paclitaxel treatment. Pharmacogenet Genomics. 2014 Sep; 24(9):451-8.
Score: 0.052
-
Glucocorticoid receptor activity contributes to resistance to androgen-targeted therapy in prostate cancer. Horm Cancer. 2014 Apr; 5(2):72-89.
Score: 0.051
-
Glucocorticoid receptor antagonism as a novel therapy for triple-negative breast cancer. Clin Cancer Res. 2013 Nov 15; 19(22):6163-72.
Score: 0.049
-
Beta-blocker use is associated with improved relapse-free survival in patients with triple-negative breast cancer. J Clin Oncol. 2011 Jul 01; 29(19):2645-52.
Score: 0.042